Kiniksa Pharmaceuticals Key Takeaways

This report highlights Kiniksa Pharmaceuticals' ongoing commercial success with Arcalyst and updates on the clinical development timelines for its pipeline assets, KPL-387 and KPL-1161.

Key Takeaways

• 1.Arcalyst's commercial progress continues to exceed expectations with 18% penetration in the 2+ recurrence patient population.
• 2.Clinical trials for KPL-387 are on track, with Phase 2 data expected in 2H26 and Phase 3 initiation by year-end 2026.
• 3.KPL-1161, a next-generation IL-1 inhibitor, remains in development with a first-in-human trial expected to start by end of 2026.

Table of Contents

• Key Takeaways
• Valuation/Risks
• Disclosure Appendix

Document Preview

Page 1 of 1

Subscribe for full accessStart Free Trial